Status:
COMPLETED
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only...
Eligibility Criteria
Inclusion
- Are not of child-bearing potential
- Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared (kg/m\^2), inclusive
- Are nonsmokers or have not smoked for at least 2 months prior to entering the study
Exclusion
- Have known allergies to insulin or its excipients, or related drugs, or history of relevant allergic reactions of any origin
- Have a history of first-degree relatives known to have diabetes mellitus
- Have used systemic glucocorticoids within 3 months prior to entry into the study
- Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to study enrollment
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01871493
Start Date
June 1 2013
End Date
September 1 2013
Last Update
October 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore, 117597